M. pneumoniae and C. pneumoniae are no relevant pathogens in critically ill patients with hospital-acquired respiratory tract infections.
Adult
Aged
Aged, 80 and over
Chlamydophila pneumoniae
/ physiology
Cohort Studies
Critical Illness
Cross Infection
/ epidemiology
Female
Germany
/ epidemiology
Humans
Incidence
Intensive Care Units
Male
Middle Aged
Mycoplasma pneumoniae
/ physiology
Respiration, Artificial
Respiratory Tract Infections
/ epidemiology
Retrospective Studies
Young Adult
Chlamydia pneumoniae
Hospital-acquired pneumonia (HAP)
Mycoplasma pneumoniae
Ventilator-associated pneumonia (VAP)
Ventilator-associated tracheobronchitis (VAT)
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
16
11
2018
accepted:
17
01
2019
pubmed:
29
1
2019
medline:
31
8
2019
entrez:
29
1
2019
Statut:
ppublish
Résumé
To assess the incidence of Mycoplasma pneumoniae and Chlamydia pneumoniae in the pathogenesis of hospital-acquired respiratory tract infections (RTIs) in critically ill patients. This is a retrospective cohort study of all ICU-patients ≥ 18 years with RTI who underwent conventional culture techniques and PCR testing for both M. pneumoniae and C. pneumoniae from respiratory tract specimens (bronchoalveolar lavage or tracheobronchial aspirates) between January 2013 to May 2017 at the Jena University Hospital. In total, 314 patients were included in the analysis. Of these, 210 (66.9%) patients were diagnosed with HAP, 65 (20.7%) with VAP and 39 (12.4%) with VAT. Overall, 73 (30.7%) patients were on mechanical ventilation on the day of microbiological examination. PCR-testing for M. pneumoniae was positive in two patients (0.6%) and for C. pneumoniae in zero patients. Our study shows that the incidence of M. pneumoniae and C. pneumoniae in the pathogenesis of hospital-acquired RTIs in critically ill patients is negligible. The results support the recommendations of the guidelines not to perform empiric therapy covering these pathogens.
Identifiants
pubmed: 30689160
doi: 10.1007/s15010-019-01273-x
pii: 10.1007/s15010-019-01273-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
471-474Références
Eur Respir J. 2002 Aug;20(2):432-9
pubmed: 12212978
Respir Care. 2005 Jun;50(6):742-63; discussion 763-5
pubmed: 15913466
Crit Care Med. 2005 Jul;33(7):1492-8
pubmed: 16003053
BMC Microbiol. 2008 Jun 11;8:93
pubmed: 18547431
Infect Control Hosp Epidemiol. 1991 Jun;12(6):356-63
pubmed: 2071878
Emerg Infect Dis. 2015 Mar;21(3):426-34
pubmed: 25693633
Pneumologie. 2016 Mar;70(3):151-200
pubmed: 26926396
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Eur Respir J. 2017 Sep 10;50(3):
pubmed: 28890434
Pneumologie. 2018 Jan;72(1):15-63
pubmed: 29341032
Am J Med. 1996 Aug;101(2):165-9
pubmed: 8757356